Adjuvanted formulations of booster vaccines
US-9375471-B2 · Jun 28, 2016 · US
Adjuvanted formulations of booster vaccines
US9931399B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9931399-B2 |
| Application number | US-201615163592-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2016 |
| Priority date | Mar 8, 2012 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
First claim
Opening claim text (preview).
We claim: 1. An immunogenic composition comprising a diphtheria toxoid, a tetanus toxoid, a pertussis toxoid, a trivalent inactivated poliovirus antigen component and an oil-in-water emulsion adjuvant, wherein the immunogenic composition includes an excess (measured in Lf units) of tetanus toxoid relative to diphtheria toxoid. 2. The immunogenic composition of claim 1 , wherein the oil-in-water emulsion adjuvant comprises squalene and/or polysorbate 80. 3. The immunogenic composition of claim 1 , wherein at least 80% by number of oil droplets in the oil-in-water emulsion adjuvant have a diameter of less than 220 nm. 4. The immunogenic composition of claim 1 , comprising a diphtheria toxoid concentration ≤4 Lf/ml. 5. The immunogenic composition of claim 1 , comprising a tetanus toxoid concentration ≤9 Lf/ml. 6. The immunogenic composition of claim 1 , comprising a pertussis toxoid concentration ≤4 μg/ml. 7. The immunogenic composition of claim 1 , further comprising a histidine buffer. 8. The immunogenic composition of claim 1 , having a pH between 6.1 and 7.9. 9. A method of raising an immune response in a subject, comprising the step of administering to the subject the immunogenic composition of claim 1 . 10. The method of claim 9 , wherein the subject has previously received a DTP vaccine as a child. 11. The method of claim 9 , wherein the oil-in-water emulsion adjuvant comprises squalene and/or polysorbate 80. 12. The method of claim 9 , wherein at least 80% by number of oil droplets in the oil-in-water emulsion have a diameter of less than 220 nm. 13. The method of claim 9 , wherein the immunogenic composition comprises a diphtheria toxoid concentration ≤4 Lf/ml. 14. The method of claim 9 , wherein the immunogenic composition comprises a tetanus toxoid concentration ≤9 Lf/ml. 15. The method of claim 9 , wherein the immunogenic composition comprises a pertussis toxoid concentration ≤4 μg/ml. 16. The method of claim 9 , wherein the immunogenic composition comprises further comprises a histidine buffer. 17. The method of claim 9 , wherein the immunogenic composition has a pH between 6.1 and 7.9.
Assignees
Inventors
Classifications
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Combination vaccines based on acellular diphtheria-tetanus-pertussis · CPC title
Organic adjuvants · CPC title
Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9931399B2 cover?
- The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).